On April 21, 2026, Rigel Pharmaceuticals Inc. RIGL announced the termination of its licensing and collaboration agreement with Eli Lilly regarding the development of ocadusertib, a drug aimed at treating autoimmune and inflammatory conditions. The agreement, which began in February 2021, will conclude on June 15, resulting in Rigel forfeiting any future milestone payments. Consequently, Rigel will regain full rights to the oral RIPK1 inhibitor, which was undergoing a phase 2a trial for severe rheumatoid arthritis as of December 2025.
https://www.gurufocus.com/news/8807571/eli-lilly-ends-collaboration-with-rigel-pharmaceuticals-lly
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.